A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
Interleukin-2 (IL-2) has been used to treat patients with metastatic melanoma and renal cell cancer for nearly two decades, and much progress has been made in ameliorating its adverse effects. One bothersome adverse effect, oral pain or oral irritation, is usually treated with an oral antifungal antibiotic, nystatin. The authors performed a prospective, randomized, double-blind, placebo-controlled trial involving 64 patients to evaluate the effect of prophylactic administration of nystatin or placebo on the development of oral irritation in patients receiving high-dose intravenous IL-2. No difference was found between patients randomized to receive nystatin or placebo in their rates of development of oral irritation, the severity of IL-2 adverse effects, the duration of their treatment, the rate of development of positive studies for oral yeast, or their pattern of experiencing other adverse effects. Thus, patients who receive high-dose intravenous IL-2 should not be treated prophylactically with nystatin to prevent oral irritation, and clinicians should seek evidence of the presence of oral thrush before using antifungal agents to treat oral pain in these patients.
Ohnmacht
G A
GA
Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892-1502, USA.
Phan
G Q
GQ
Mavroukakis
S A
SA
Steinberg
S M
SM
Shea
Y R
YR
Witebsky
F G
FG
McIntyre
L S
LS
Goodwin
R S
RS
Muehlbauer
P M
PM
Morton
K E
KE
Rogers-Freezer
L J
LJ
Seipp
C A
CA
Rosenberg
S A
SA
Marincola
F M
FM
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced / Q000517:prevention & control*; D009761:Nystatin / Q000627:therapeutic use*; D010919:Placebos; D011446:Prospective Studies
D000935:Antifungal Agents; D007376:Interleukin-2; D010919:Placebos; D009761:Nystatin